[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postoperative-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postoperative-bleeding":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,81,107,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100532089","tranexamic-acid-use-on-pain-mobility-and-bleeding-following-total-hip-and-total-knee-arthroplasty-100532089",false,"NCT06208267","Tranexamic Acid Use on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty","The Impact of Additional Post-operative Doses of Tranexamic Acid on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty: A Randomized Controlled Trial","TXA","Inclusion Criteria:\n\n° All adults undergoing primary TKA and THA at St-Mary's Hospital\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Known hypersensitivity or allergy to TXA\n* Previous history of thromboembolic disease\n* Active malignancy (all current cancers other than local skin cancer)\n* Significant renal disease (hematuria, dialysis, kidney transplant)\n* History of convulsions\n* Known defective colour vision\n* Inability or unwillingness to use MyMobility app\n* Unable to communicate in French or English",true,"ALL","18 Years",{"count":21,"type":22},210,"ESTIMATED","INTERVENTIONAL",[25],"NA","Tranexamic acid (TXA) is an anti-fibrinolytic agent developed in the 1960s that has been safely used to reduce blood loss, transfusion rates and bleeding-associated mortality in trauma, obstetrics and orthopedic surgery, including hip fracture care and arthroplasty.\n\nThe efficacy and safety profile of TXA has been extensively studied in numerous clinical trials and observational studies. Its wide range of applications, combined with its favourable risk-benefit ratio, has led to the incorporation of TXA into clinical guidelines and protocols worldwide.\n\nThis RCT aims to compare the current standard dosing for TXA to additional TXA doses given orally post-operatively for THA and TKA patients. The goal is to compare the following between study groups: visible bleeding on post-operative dressing, mobilization (steps, amount of time moving around), pain (visual analog scale), function (Oxford hip and knee scales) and ROM at four to six weeks.",[28],"Postoperative Bleeding","RECRUITING","2026-04-22",{"date":32,"type":33},"2026-04-28","ACTUAL",{"date":35,"type":33},"2025-08-20",{"date":37,"type":22},"2027-07",{"name":39,"class":40},"St. Mary's Research Center, Canada","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":59,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":41},"100619498","genecard---the-use-of-genetic-epigenetic-metabolomic-proteomic-and-microbiotic-markers-image-and-voice-biomarker-analyses-and-pre--and-intraoperative-clinical-data---to-predict-early-complications-after-cardiac-surgery-100619498","NCT07345403","GENECARD - the Use of Genetic, Epigenetic, Metabolomic, Proteomic and Microbiotic Markers, Image and Voice Biomarker Analyses, and Pre- and Intraoperative Clinical Data - to Predict Early Complications After Cardiac Surgery.","GENECARD","Inclusion Criteria:\n\n* Adults (≥18 years old)\n* Undergoing elective cardiac surgery\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Age below 18 years\n* Lack of informed consent\n* Prior or planned solid organ transplantation\n* Prior or planned bone marrow transplantation",{"count":50,"type":22},3000,"30 Days","OBSERVATIONAL","The goal of this observational cohort study is to prove whether genetic, epigenetic, transcriptomic, proteomic, metabolomic, imaging, voice, and clinical markers can improve prediction of early complications after cardiac surgery in adult patients.\n\nThe main questions it aims to answer are:\n\nWhich biological and clinical markers are associated with: new-onset atrial fibrillation (NOAF), acute kidney injury (AKI), postoperative delirium (POD), vasoplegia, postoperative bleeding and 30-day mortality? Can combining these markers improve early prediction of postoperative complications compared with current clinical risk scores?\n\nResearchers will analyze a wide range of data collected before, during, and after cardiac surgery and compare patients who develop early complications with those who do not to identify risk factors and early biomarkers.\n\nParticipants will:\n\nProvide biological samples (blood, urine, stool) before and after surgery for genetic, epigenetic, transcriptomic, proteomic, metabolomic, microbiome, and laboratory testing.\n\nUndergo standard preoperative and intraoperative imaging and clinical assessments.\n\nAllow collection of clinical data related to postoperative outcomes (For some participants) have voice and video recordings performed to help identify early signs of postoperative delirium.\n\nThis study aims to improve early detection of postoperative complications and support development of personalized diagnostic and treatment strategies for patients undergoing cardiac surgery.",[55,28,56,57,58],"Postoperative Delirium (POD)","Acute Kidney Injury","Atrial Fibrillation (AF)","Vasoplegia",[60,61,62,56,63,58,64,65,66,67,68,69,70],"Cardiac Surgery","Postoperative Complications","Atrial Fibrillation","Postoperative Delirium","Biomarkers","Multi-omics","Risk Prediction","Epigenetics","genetics","microbiota","metabolomics","NOT_YET_RECRUITING","2026-01-08",{"date":74,"type":33},"2026-01-15",{"date":76,"type":22},"2026-01-01",{"date":78,"type":22},"2029-12-31",{"name":80,"class":40},"Medical University of Gdansk",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":41},"100520523","phase-2-tranexamic-acid-in-nasal-mohs-reconstruction-100520523","NCT06057675","Tranexamic Acid in Nasal Mohs Reconstruction","Subcutaneous Tranexamic Acid in Nasal Mohs Local Flap Reconstruction: Perioperative Bleeding, Edema, and Ecchymosis","Inclusion Criteria:\n\n1. Adults at least 18 years of age undergoing local flap reconstruction (bilobe flap, note flap dorsal nasal flap, advancement flap) of a nasal defect following Mohs micrographic surgery. Reconstructive procedures will be performed by Drs. Yang or Patel in the division of Facial Plastic Surgery in the Department of Otolaryngology, Head and Neck Surgery at Vanderbilt University Medical Center.\n2. No other facial plastic procedure or sinus surgery performed simultaneously.\n3. Lack of all the below exclusion criteria.\n\nExclusion Criteria:\n\n1. Known allergy to TXA\n2. Intracranial bleeding\n3. Known defective color vision\n4. History of venous or arterial thromboembolism\n5. History of coagulation disorder\n6. Active thromboembolic disease\n7. Severe renal impairment (diagnosis of chronic kidney disease)\n8. History of acute myocardial infarction\n9. History of stroke\n10. History of seizure\n11. History of liver failure\n12. Preoperative lab results indicating thrombocytopenia (platelets \\\u003C150,000), increased bleeding risk (PT over 45, INR over 1.2).",{"count":89,"type":22},100,[91],"PHASE2","This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.",[28,94],"Skin Cancer Face",[96,97],"Tranexamic Acid","Mohs Reconstruction","2025-08-17",{"date":100,"type":33},"2025-08-19",{"date":102,"type":33},"2024-03-19",{"date":104,"type":22},"2026-06",{"name":106,"class":40},"Vanderbilt University Medical Center",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":41},"100589958","observational-study-of-platelet-dysfunction-assessed-by-thromboelastography-in-cardiovascular-surgery-displateg-100589958","NCT06961175","Observational Study of Platelet Dysfunction Assessed by Thromboelastography in Cardiovascular Surgery (DISPLATEG)","Observational Study of Preoperative or Extracorporeal Circulation-induced Platelet Dysfunction Assessed by Thromboelastography in Non-antiplatelet-treated Patients Undergoing Cardiovascular Surgery (DISPLATEG Study)","DISPLATEG","Inclusion Criteria:\n\n* Over 18 years of age.\n* Patients undergoing elective surgery under CPB.\n* Patients must be duly informed and have signed the informed consent form.\n* ASA status I-IV.\n* Sufficient intellectual capacity to understand the procedure.\n* Normal preoperative coagulation study and platelet count.\n\nExclusion Criteria:\n\n* Failure to meet the criteria listed above.\n* Preoperative administration of antiplatelet agents with an inadequate washout period (5 days for clopidogrel and ticagrelor and 7 days for plasugrel).\n* Preoperative administration of anticoagulants with an inadequate washout period.\n* Thrombopenia \\\u003C100,000 platelets or anemia \\\u003C11 g\u002FdL",{"count":116,"type":22},180,"Perioperative bleeding requiring blood transfusion is common during cardiovascular surgery, especially in procedures requiring cardiopulmonary bypass. Adenosine diphosphate (ADP) plays a fundamental role in platelet function. Several studies have shown that some patients not receiving antiplatelet therapy undergoing cardiovascular surgery have decreased platelet ADP receptor activity; the prevalence of this condition can be as high as 36%.\n\nFurthermore, extracorporeal circulation itself has been shown to cause a reduction in platelet function. Platelet dysfunction due to reduced platelet receptor activity after cardiac surgery is potentially a common cause of bleeding, perioperative blood transfusion, and surgical reexploration in patients not receiving antiplatelet agents. However, these studies are conducted with few patients and present some contradictory results, so the evidence is still scarce.\n\nThe study hypothesis is that preoperative platelet dysfunction for ADP measured by TEG® Platelet Mapping™ is associated with a higher incidence of moderate-severe bleeding after CPB in patients undergoing cardiovascular surgery.",[119,60,28],"Blood Platelet Disorders","2025-08-04",{"date":122,"type":33},"2025-08-08",{"date":124,"type":33},"2025-05-01",{"date":126,"type":22},"2026-12",{"name":128,"class":40},"Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":135,"minAge":19,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":140,"conditions":141,"keywords":144,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":152,"leadSponsor":154,"locationsCount":41},"100590585","phase-3-topical-estrogen-brief-intervention-to-improve-postoperative-experience-for-transgender-men-undergoing-hysterectomy-100590585","NCT06969326","Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy","Inclusion Criteria:\n\n1. Gender diverse\u002Ftransgender men\n2. Age 18 or older\n3. Have been on testosterone for at least 6 months with plan to undergo gender-affirming hysterectomy and are willing to be randomized to the use of topical estrogen postoperatively.\n4. Have stable physical and mental health\n5. No contraindications to estrogen therapy\n6. Must be proficient in English or Spanish\n7. Must have access to a device to receive text messages for study follow up\n8. Must agree to allow their medical data to be used for research purposes\n\nExclusion Criteria:\n\n1. Under age 18\n2. Have not been on testosterone for at least 6 months prior to planned hysterectomy\n3. Known allergy to topical estrogen","FEMALE",{"count":137,"type":22},48,[139],"PHASE3","The purpose of this study is to determine if applying a single dose of topical estrogen cream in the operating room at the end of your hysterectomy (removal of uterus and cervix) improves the postoperative experience with bleeding and potential symptoms of dysphoria (a feeling of discomfort or distress). Topical estrogen cream is sometimes used if patients have increased risk of bleeding with surgery but is not currently utilized in a consistent way. This study aims to answer the question of whether this is a helpful treatment and should be included in standard postoperative care.",[28,142,143],"Gender Dysphoria","Hysterectomy",[145,146,147],"gender dysphoria","gender affirmation","hysterectomy","2025-05-08",{"date":150,"type":33},"2025-05-13",{"date":124,"type":33},{"date":153,"type":22},"2026-12-01",{"name":155,"class":40},"Women and Infants Hospital of Rhode Island"]